Department of Endocrinology, First Affiliated Hospital of Harbin Medical University, Harbin, China.
J Cardiovasc Pharmacol. 2010 Jan;55(1):21-5. doi: 10.1097/FJC.0b013e3181bfb1df.
The aim of this study was to determine the effects of simvastatin and atorvastatin on the markers of oxidative stress in patients with type 2 diabetes mellitus (T2DM). The study population consisted of 151 patients with T2DM and 147 control individuals. The patients with T2DM were treated with 40 mg of simvastatin per day or 10 mg of simvastatin per day. Waist circumference, body mass index, blood pressure, and glucose and insulin values were obtained; and fasting serum lipids, malondialdehyde, nitric oxide, glutathione peroxidase and superoxide dismutase activity were determined before and after 12 weeks of treatment. Statin treatment significantly decreased plasma lipids in all patients with diabetes (P < 0.05). No significant differences were detected between the two treatment groups with respect to plasma lipid profile (P < 0.05). In addition, the effects of atorvastatin to increase nitric oxide concentration (33.28 +/- 3.37 micromol/L versus 27.32 +/- 4.15 micromol/L, P < 0.05) and glutathione peroxidase (17.67 +/- 1.41 micromol/L versus 14.28 +/- 1.65 micromol/L, P < 0.05), superoxide dismutase activity (34.28 +/- 4.71 micromol/L versus 27.91 +/- 3.38 micromol/L, P < 0.05 ) and decreased malondialdehyde level (49.52 +/- 5.67 micromol/L versus 42.08 +/- 5.16 micromol/L, P < 0.05) were significantly greater in patients with T2DM compared with simvastatin. The changes in the markers of oxidative stress did not correlate with the changes in plasma lipid profile (P > 0.05). This study suggested that atorvastatin reduced oxidative stress more effectively than simvastatin in patients with T2DM and the clinical benefits of statins may be independent of their cholesterol-lowering effects.
本研究旨在探讨辛伐他汀和阿托伐他汀对 2 型糖尿病（T2DM）患者氧化应激标志物的影响。研究人群包括 151 例 T2DM 患者和 147 名对照个体。T2DM 患者每天接受 40 毫克辛伐他汀或 10 毫克辛伐他汀治疗。治疗前和治疗 12 周后，测量腰围、体重指数、血压以及血糖和胰岛素值，并检测空腹血清脂质、丙二醛、一氧化氮、谷胱甘肽过氧化物酶和超氧化物歧化酶活性。他汀类药物治疗显著降低了所有糖尿病患者的血浆脂质（P<0.05）。两组患者的血脂谱无显著差异（P<0.05）。此外，阿托伐他汀增加一氧化氮浓度（33.28±3.37μmol/L 对 27.32±4.15μmol/L，P<0.05）和谷胱甘肽过氧化物酶（17.67±1.41μmol/L 对 14.28±1.65μmol/L，P<0.05）、超氧化物歧化酶活性（34.28±4.71μmol/L 对 27.91±3.38μmol/L，P<0.05）和降低丙二醛水平（49.52±5.67μmol/L 对 42.08±5.16μmol/L，P<0.05）的作用在 T2DM 患者中明显大于辛伐他汀。氧化应激标志物的变化与血浆脂质谱的变化无关（P>0.05）。本研究表明，阿托伐他汀在 T2DM 患者中比辛伐他汀更有效地降低氧化应激，他汀类药物的临床益处可能与其降脂作用无关。
